Key result
Enterovirus infection triggers late-onset giant cell myocarditis during immune checkpoint inhibitor therapy.
Why the study?
Immune checkpoint inhibitor therapy improves cancer prognosis but can cause myocarditis, with limited data on late-onset giant cell myocarditis due to enterovirus during treatment.
Design
Other
Authors
Loading...
Immune checkpoint inhibitor (ICI) therapy has significantly improved the prognosis of many advanced cancers. ICIs target cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), or programmed cell death-ligand 1 (PD-L1) and increase the antitumor immune response. Several
Key points are not available for this paper at this time.
Mirabel et al. (2020) studied this question. Immune checkpoint inhibitor therapy was complicated by late-onset giant cell myocarditis due to enterovirus infection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: